JP2009502196A - Ｂｋウイルス検出のための方法および組成物 - Google Patents

Ｂｋウイルス検出のための方法および組成物 Download PDF

Info

Publication number: JP2009502196A
Authority: JP; Japan
Prior art keywords: nucleic acid; sequence; bkv; target; seq
Prior art date: 2005-08-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2008525040A

Other languages

English (en)

Japanese (ja)

Other versions

JP2009502196A5 (2

Inventor

チェン，ファン

コン，リリー，アイ．

チェン，ジュールズ

ジャナティプール，メールダッド

Original Assignee

フォーカスダイアグノスティックスインコーポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-08-02

Filing date

2006-07-25

Publication date

2009-01-29

2006-07-25 Application filed by フォーカスダイアグノスティックスインコーポレイテッド filed Critical フォーカスダイアグノスティックスインコーポレイテッド

2009-01-29 Publication of JP2009502196A publication Critical patent/JP2009502196A/ja

2009-09-10 Publication of JP2009502196A5 publication Critical patent/JP2009502196A5/ja

Status Pending legal-status Critical Current

Links

241000829111 Human polyomavirus 1 Species 0.000 title claims abstract description 190
238000000034 method Methods 0.000 title claims abstract description 140
238000001514 detection method Methods 0.000 title claims abstract description 89
239000000203 mixture Substances 0.000 title abstract description 13
150000007523 nucleic acids Chemical class 0.000 claims abstract description 284
102000039446 nucleic acids Human genes 0.000 claims abstract description 225
108020004707 nucleic acids Proteins 0.000 claims abstract description 225
239000000523 sample Substances 0.000 claims abstract description 211
239000002773 nucleotide Substances 0.000 claims description 113
125000003729 nucleotide group Chemical group 0.000 claims description 113
238000003199 nucleic acid amplification method Methods 0.000 claims description 92
230000003321 amplification Effects 0.000 claims description 91
230000000295 complement effect Effects 0.000 claims description 76
108091028043 Nucleic acid sequence Proteins 0.000 claims description 55
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
239000013615 primer Substances 0.000 description 163
238000003556 assay Methods 0.000 description 69
108020004414 DNA Proteins 0.000 description 47
239000002987 primer (paints) Substances 0.000 description 35
238000003752 polymerase chain reaction Methods 0.000 description 34
238000009396 hybridization Methods 0.000 description 32
108091034117 Oligonucleotide Proteins 0.000 description 28
102000040430 polynucleotide Human genes 0.000 description 27
108091033319 polynucleotide Proteins 0.000 description 27
239000002157 polynucleotide Substances 0.000 description 27
238000004458 analytical method Methods 0.000 description 26
239000012634 fragment Substances 0.000 description 25
239000002585 base Substances 0.000 description 21
108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
241000701460 JC polyomavirus Species 0.000 description 19
239000002751 oligonucleotide probe Substances 0.000 description 18
239000007787 solid Substances 0.000 description 17
RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 16
241000700605 Viruses Species 0.000 description 15
239000012472 biological sample Substances 0.000 description 15
108020005187 Oligonucleotide Probes Proteins 0.000 description 14
102000053602 DNA Human genes 0.000 description 13
238000006243 chemical reaction Methods 0.000 description 13
230000027455 binding Effects 0.000 description 12
239000003153 chemical reaction reagent Substances 0.000 description 12
238000003786 synthesis reaction Methods 0.000 description 12
230000015572 biosynthetic process Effects 0.000 description 11
238000013461 design Methods 0.000 description 11
230000035945 sensitivity Effects 0.000 description 11
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 10
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 10
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 10
102000004190 Enzymes Human genes 0.000 description 9
108090000790 Enzymes Proteins 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
239000002253 acid Substances 0.000 description 9
150000001875 compounds Chemical class 0.000 description 9
238000012163 sequencing technique Methods 0.000 description 9
238000011895 specific detection Methods 0.000 description 9
239000000126 substance Substances 0.000 description 9
239000003155 DNA primer Substances 0.000 description 8
150000007513 acids Chemical class 0.000 description 8
239000000463 material Substances 0.000 description 8
229920000642 polymer Polymers 0.000 description 8
230000003612 virological effect Effects 0.000 description 8
239000000872 buffer Substances 0.000 description 7
238000005259 measurement Methods 0.000 description 7
-1 phosphotriesters Chemical class 0.000 description 7
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
101710163270 Nuclease Proteins 0.000 description 6
239000000975 dye Substances 0.000 description 6
238000007899 nucleic acid hybridization Methods 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
108020004635 Complementary DNA Proteins 0.000 description 5
241001505332 Polyomavirus sp. Species 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
239000012491 analyte Substances 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
108091036078 conserved sequence Proteins 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000007850 fluorescent dye Substances 0.000 description 5
230000007062 hydrolysis Effects 0.000 description 5
238000006460 hydrolysis reaction Methods 0.000 description 5
238000012986 modification Methods 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000002887 multiple sequence alignment Methods 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
108010017826 DNA Polymerase I Proteins 0.000 description 4
102000004594 DNA Polymerase I Human genes 0.000 description 4
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
108020004711 Nucleic Acid Probes Proteins 0.000 description 4
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 4
230000008901 benefit Effects 0.000 description 4
238000010804 cDNA synthesis Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
229910052751 metal Inorganic materials 0.000 description 4
239000002184 metal Substances 0.000 description 4
238000012544 monitoring process Methods 0.000 description 4
239000002853 nucleic acid probe Substances 0.000 description 4
210000002381 plasma Anatomy 0.000 description 4
238000006116 polymerization reaction Methods 0.000 description 4
230000008569 process Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000000243 solution Substances 0.000 description 4
241000894007 species Species 0.000 description 4
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
108090001008 Avidin Proteins 0.000 description 3
208000027580 BK-virus nephropathy Diseases 0.000 description 3
206010062016 Immunosuppression Diseases 0.000 description 3
108091093037 Peptide nucleic acid Proteins 0.000 description 3
206010065381 Polyomavirus-associated nephropathy Diseases 0.000 description 3
239000004793 Polystyrene Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000011088 calibration curve Methods 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000005547 deoxyribonucleotide Substances 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
230000001506 immunosuppresive effect Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
208000017169 kidney disease Diseases 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
229920002223 polystyrene Polymers 0.000 description 3
238000003753 real-time PCR Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000000758 substrate Substances 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
238000013519 translation Methods 0.000 description 3
230000014616 translation Effects 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
XUVKSPPGPPFPQN-UHFFFAOYSA-N 10-Methyl-9(10H)-acridone Chemical compound C1=CC=C2N(C)C3=CC=CC=C3C(=O)C2=C1 XUVKSPPGPPFPQN-UHFFFAOYSA-N 0.000 description 2
108010037497 3'-nucleotidase Proteins 0.000 description 2
108091093088 Amplicon Proteins 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
108091028664 Ribonucleotide Proteins 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
108020005202 Viral DNA Proteins 0.000 description 2
PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
239000003513 alkali Substances 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
210000004381 amniotic fluid Anatomy 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
239000011616 biotin Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
239000010931 gold Substances 0.000 description 2
229910052737 gold Inorganic materials 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
229920001519 homopolymer Polymers 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
238000002372 labelling Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
230000011987 methylation Effects 0.000 description 2
238000007069 methylation reaction Methods 0.000 description 2
238000001668 nucleic acid synthesis Methods 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
238000011002 quantification Methods 0.000 description 2
238000010791 quenching Methods 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
239000002336 ribonucleotide Substances 0.000 description 2
125000002652 ribonucleotide group Chemical group 0.000 description 2
238000005464 sample preparation method Methods 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000011896 sensitive detection Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
230000002194 synthesizing effect Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
229940113082 thymine Drugs 0.000 description 2
229940035893 uracil Drugs 0.000 description 2
238000005406 washing Methods 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
ORZCDYRUIIDJNS-UHFFFAOYSA-N 2-methylacridine-1-carboxylic acid Chemical compound CC1=C(C2=CC3=CC=CC=C3N=C2C=C1)C(=O)O ORZCDYRUIIDJNS-UHFFFAOYSA-N 0.000 description 1
108020005345 3' Untranslated Regions Proteins 0.000 description 1
VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
108020003589 5' Untranslated Regions Proteins 0.000 description 1
BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
206010055181 BK virus infection Diseases 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
229930182476 C-glycoside Natural products 0.000 description 1
150000000700 C-glycosides Chemical class 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
108020001019 DNA Primers Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
241000701832 Enterobacteria phage T3 Species 0.000 description 1
101150026303 HEX1 gene Proteins 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
101710203526 Integrase Proteins 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
238000002944 PCR assay Methods 0.000 description 1
108010010677 Phosphodiesterase I Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
108091034057 RNA (poly(A)) Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
241000053227 Themus Species 0.000 description 1
241000205180 Thermococcus litoralis Species 0.000 description 1
241000589500 Thermus aquaticus Species 0.000 description 1
108091061763 Triple-stranded DNA Proteins 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
239000012670 alkaline solution Substances 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
238000002820 assay format Methods 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000010835 comparative analysis Methods 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
239000005289 controlled pore glass Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000004163 cytometry Methods 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
108700020302 erbB-2 Genes Proteins 0.000 description 1
238000010931 ester hydrolysis Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000005283 ground state Effects 0.000 description 1
210000004251 human milk Anatomy 0.000 description 1
235000020256 human milk Nutrition 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000012606 in vitro cell culture Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
229910044991 metal oxide Inorganic materials 0.000 description 1
150000004706 metal oxides Chemical class 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000007918 pathogenicity Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
150000008298 phosphoramidates Chemical class 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000037452 priming Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
239000002213 purine nucleotide Substances 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
239000002719 pyrimidine nucleotide Substances 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
230000007420 reactivation Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008085 renal dysfunction Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
229940048086 sodium pyrophosphate Drugs 0.000 description 1
229940048098 sodium sarcosinate Drugs 0.000 description 1
ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
210000001138 tear Anatomy 0.000 description 1
ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000005382 thermal cycling Methods 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
238000004448 titration Methods 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Virology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

JP2008525040A 2005-08-02 2006-07-25 Ｂｋウイルス検出のための方法および組成物 Pending JP2009502196A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US70521705P	2005-08-02	2005-08-02
US11/246,904 US7892795B2 (en)	2005-08-02	2005-10-06	Methods and compositions for detecting BK virus
PCT/US2006/029243 WO2007016275A2 (en)	2005-08-02	2006-07-25	Methods and compositions for detecting bk virus

Publications (2)

Publication Number	Publication Date
JP2009502196A true JP2009502196A (ja)	2009-01-29
JP2009502196A5 JP2009502196A5 (2)	2009-09-10

Family

ID=37709186

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2008525040A Pending JP2009502196A (ja)	2005-08-02	2006-07-25	Ｂｋウイルス検出のための方法および組成物

Country Status (8)

Country	Link
US (4)	US7892795B2 (2)
EP (2)	EP1910578B1 (2)
JP (1)	JP2009502196A (2)
CN (3)	CN110423844B (2)
AU (1)	AU2006275803B2 (2)
CA (1)	CA2617635C (2)
ES (1)	ES2552725T3 (2)
WO (1)	WO2007016275A2 (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2020501600A (ja) *	2016-11-09	2020-01-23	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｂｋウイルスの検出のための組成物および方法
WO2020256529A1 (ko) *	2019-06-21	2020-12-24	울산대학교 산학협력단	신장이식 후 bk 바이러스 감염성 신병증의 진단 또는 신장이식 후 환자의 예후 예측을 위한 소변 엑소좀 바이오마커

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7892795B2 (en) *	2005-08-02	2011-02-22	Focus Diagnostics, Inc.	Methods and compositions for detecting BK virus
US20090246754A1 (en) *	2008-02-19	2009-10-01	Intelligent Mdx	Optimized probes and primers and methods of using same for the detection and quantitation of bk virus
KR20110011600A (ko) *	2008-02-20	2011-02-08	이와키, 코수케, 켄	폴리오마바이러스 검출
US20090258342A1 (en) *	2008-04-09	2009-10-15	Intelligent Medical Devices, Inc.	Optimized probes and primers and methods of using same for the detection, quantification and grouping of hiv-1
CN102344970B (zh) *	2010-07-27	2013-01-23	温州医学院附属第一医院	同时检测人cmv和bk病毒dna的引物序列及定量检测试剂盒
CN102154523B (zh) *	2011-04-07	2013-01-02	温岭市第一人民医院	检测人bk病毒核酸的引物与荧光探针及其应用
CN102690894B (zh) *	2011-06-08	2013-05-01	中国人民解放军第三〇九医院	一种bk病毒的检测方法、其试剂盒及应用
CN103093120A (zh) *	2011-11-08	2013-05-08	北京健数通生物计算技术有限公司	高通量检测脊椎动物病原体基因芯片的探针设计方法
CN104745723A (zh) *	2015-01-30	2015-07-01	湖北永邦医疗科技有限公司	一种用于检测bk病毒的引物、探针和试剂盒
JP7532257B2 (ja) *	2018-03-02	2024-08-13	アカデミシュ・ジークンホイス・ライデン・ハー・オー・デー・エン・ライドス・ユニヴェルシタイル・メディシュ・セントルム	ポリオーマウイルス複製の阻害
FR3082524B1 (fr) *	2018-06-18	2022-03-25	Univ Paris Sud	Methode de stratification du risque de nephropathie a bk-virus apres transplantation renale
WO2020086546A1 (en) *	2018-10-22	2020-04-30	Gen-Probe Incorporated	Compositions and methods for amplifying, detecting or quantifying human polyomavirus bk virus
CN111733298B (zh) *	2020-08-25	2020-11-20	圣湘生物科技股份有限公司	检测多瘤病毒并分型的组合物、试剂盒、方法及其用途
TWI833069B (zh)	2021-03-17	2024-02-21	國防醫學院	核酸探針組、核酸側流檢測套組以及該核酸側流檢測套組之用途
CN114107571B (zh) *	2022-01-18	2024-06-21	复旦大学附属中山医院	用于bk病毒lamp检测的试剂盒
CN115029485A (zh) *	2022-06-20	2022-09-09	广东永诺医疗科技有限公司	一种基于微滴式数字pcr的bkv病毒检测试剂盒

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4318846A (en)	1979-09-07	1982-03-09	Syva Company	Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers
US4458066A (en)	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
US4415732A (en)	1981-03-27	1983-11-15	University Patents, Inc.	Phosphoramidite compounds and processes
US4605735A (en)	1983-02-14	1986-08-12	Wakunaga Seiyaku Kabushiki Kaisha	Oligonucleotide derivatives
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4757141A (en)	1985-08-26	1988-07-12	Applied Biosystems, Incorporated	Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4889818A (en)	1986-08-22	1989-12-26	Cetus Corporation	Purified thermostable enzyme
US5541308A (en) *	1986-11-24	1996-07-30	Gen-Probe Incorporated	Nucleic acid probes for detection and/or quantitation of non-viral organisms
US5283174A (en)	1987-09-21	1994-02-01	Gen-Probe, Incorporated	Homogenous protection assay
US5639604A (en)	1987-09-21	1997-06-17	Gen-Probe Incorporated	Homogeneous protection assay
US6004745A (en)	1987-09-21	1999-12-21	Gen-Probe Incorporated	Hybridization protection assay
US5585481A (en)	1987-09-21	1996-12-17	Gen-Probe Incorporated	Linking reagents for nucleotide probes
US4914210A (en)	1987-10-02	1990-04-03	Cetus Corporation	Oligonucleotide functionalizing reagents
US5185439A (en)	1987-10-05	1993-02-09	Gen-Probe Incorporated	Acridinium ester labelling and purification of nucleotide probes
CA1340807C (en)	1988-02-24	1999-11-02	Lawrence T. Malek	Nucleic acid amplification process
JP2650159B2 (ja)	1988-02-24	1997-09-03	アクゾ・ノベル・エヌ・ベー	核酸増幅方法
US5849481A (en)	1990-07-27	1998-12-15	Chiron Corporation	Nucleic acid hybridization assays employing large comb-type branched polynucleotides
US5213796A (en)	1991-05-06	1993-05-25	Dana Farber Cancer Institute	Assay for polyomavirus in humans and uses thereof
US5538848A (en)	1994-11-16	1996-07-23	Applied Biosystems Division, Perkin-Elmer Corp.	Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US6127121A (en) *	1998-04-03	2000-10-03	Epoch Pharmaceuticals, Inc.	Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination
WO2001066148A1 (en)	2000-03-08	2001-09-13	Neurosearch A/S	A method of sensitising endothelial cells to prodrugs
US6605602B1 (en) *	2001-09-28	2003-08-12	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Method of treating BK virus nephropathy
BRPI0214741B1 (pt) *	2001-12-08	2015-05-12	Seegene Inc	Iniciador de controle de anelamento para melhorar a especificidade de anelamento na amplificação de ácido nucléico, Kit, Métodos para amplificar seqüências de ácido nucléico de um DNA e seqüência de ácido nucléico alvo ou uma mistura de ácidos nucléicos, para detectar a complementaridade de DNA ao mRNA diferencialmente expresso em duas ou mais amostras de ácido nucléico, para amplificar rapidamente um fragmento de CDNA alvo, para amplificar uma população de CDNAs de filamento duplo de comprimento completo complementar aos mRNAS, e CDNAs de filamento duplo enriquecidos em 5 complementares aos mRNAS, para amplificar mais do que uma seqüência de nucleotídeo alvo simultaneamente, para produzir uma impressão digital de DNA de gDNA, e de RNA de uma amostra de mRNA, para identificar segmentos de homologia conservada em uma família de multigene a partir de uma amostra de mRNA, para identificar uma variação de nucleotídeo em um ácido nucléico alvo, para a mutagênese em um ácido nucléico alvo, e, uso do iniciador
US7892795B2 (en) *	2005-08-02	2011-02-22	Focus Diagnostics, Inc.	Methods and compositions for detecting BK virus
WO2007127919A2 (en) *	2006-04-28	2007-11-08	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of a gene from the jc virus
US20080003565A1 (en) *	2006-05-02	2008-01-03	Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services	Viral nucleic acid microarray and method of use

2005
- 2005-10-06 US US11/246,904 patent/US7892795B2/en active Active
2006
- 2006-07-25 AU AU2006275803A patent/AU2006275803B2/en active Active
- 2006-07-25 WO PCT/US2006/029243 patent/WO2007016275A2/en not_active Ceased
- 2006-07-25 EP EP06788689.5A patent/EP1910578B1/en active Active
- 2006-07-25 CN CN201910529553.9A patent/CN110423844B/zh active Active
- 2006-07-25 JP JP2008525040A patent/JP2009502196A/ja active Pending
- 2006-07-25 CN CN200680034771.6A patent/CN101511995B/zh active Active
- 2006-07-25 CA CA2617635A patent/CA2617635C/en active Active
- 2006-07-25 CN CN201510303094.4A patent/CN104862422B/zh active Active
- 2006-07-25 EP EP12196497.7A patent/EP2662456A1/en not_active Withdrawn
- 2006-07-25 ES ES06788689.5T patent/ES2552725T3/es active Active
2011
- 2011-01-12 US US13/005,490 patent/US8748092B2/en active Active
2014
- 2014-04-29 US US14/264,462 patent/US9745638B2/en not_active Expired - Lifetime
2017
- 2017-08-22 US US15/683,036 patent/US10801078B2/en not_active Expired - Lifetime

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2020501600A (ja) *	2016-11-09	2020-01-23	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｂｋウイルスの検出のための組成物および方法
WO2020256529A1 (ko) *	2019-06-21	2020-12-24	울산대학교 산학협력단	신장이식 후 bk 바이러스 감염성 신병증의 진단 또는 신장이식 후 환자의 예후 예측을 위한 소변 엑소좀 바이오마커

Also Published As

Publication number	Publication date
EP1910578A4 (en)	2009-12-09
CA2617635C (en)	2015-07-21
CN104862422A (zh)	2015-08-26
EP1910578B1 (en)	2015-06-10
ES2552725T3 (es)	2015-12-01
US20110143349A1 (en)	2011-06-16
WO2007016275A2 (en)	2007-02-08
AU2006275803A1 (en)	2007-02-08
EP1910578A2 (en)	2008-04-16
US20070031825A1 (en)	2007-02-08
CN110423844B (zh)	2023-10-24
US9745638B2 (en)	2017-08-29
US7892795B2 (en)	2011-02-22
EP2662456A1 (en)	2013-11-13
US20140349275A1 (en)	2014-11-27
HK1115613A1 (en)	2008-12-05
CA2617635A1 (en)	2007-02-08
AU2006275803B2 (en)	2012-08-30
US20180044742A1 (en)	2018-02-15
CN101511995A (zh)	2009-08-19
CN101511995B (zh)	2015-07-01
CN110423844A (zh)	2019-11-08
US10801078B2 (en)	2020-10-13
WO2007016275A3 (en)	2009-04-30
US8748092B2 (en)	2014-06-10
CN104862422B (zh)	2019-07-16

Legal Events

Date	Code	Title	Description
2009-07-24	A524	Written submission of copy of amendment under article 19 pct	Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20090723
2009-07-24	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090723
2009-08-13	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090723
2011-12-07	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111206
2012-03-06	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120305
2012-03-13	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120312
2012-08-01	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120731

Publication	Publication Date	Title
US10801078B2 (en)	2020-10-13	Methods and compositions for detecting BK virus
JP6026401B2 (ja)	2016-11-16	パルボウイルスｂ１９についての診断アッセイ
US8119338B2 (en)	2012-02-21	Methods and compositions for detecting rhinoviruses
MXPA04012501A (es)	2005-02-17	Identificacion de oligonucleotidos para la captura, deteccion y cuatificacion de acido nucleico viral de la hepatitis a.
JP2012513757A (ja)	2012-06-21	Ｃ型肝炎ウイルスの検出用プライマー及びプローブ
AU2012261529B2 (en)	2016-11-03	Methods and compositions for detecting BK virus
HK1115613B (en)	2016-04-22	Methods and compositions for detecting bk virus

JP2009502196A - Ｂｋウイルス検出のための方法および組成物 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (2)

Family

ID=37709186

Family Applications (1)

Country Status (8)

Cited By (2)

Families Citing this family (16)

Family Cites Families (27)

Cited By (2)

Also Published As

Similar Documents

Legal Events